Urade Masahiro
Department of Oral and Maxillofacial Surgery, Hyogo College of Medicine.
Clin Calcium. 2011 Mar;21(3):420-7.
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) develops as a side effect of long-term administration of bisphosphonates (BP) , especially intravenous preparations. The lesion is a new disease entity which was first reported in 2003 in the United States. Since then, the number of patients with BRONJ is increasing year by year. In Japan, the first case was reported in 2006, and at that time 30 cases of BRONJ were registered in the nationwide survey by the Japanese Society of Oral and Maxillofacial Surgeons. However, the patients with BRONJ increased rapidly in the second survey after 2 years, and more than 250 cases of BRONJ which met the criteria of clinical diagnosis were determined. Approximately 95% of the BRONJ patients received intravenous BPs and less than 5% received oral BPs in the United States and European Union, whereas 58% of the patients received intravenous BPs and 40% received oral BPs in Japan. The relative ratio of BRONJ associated with the use of oral BPs was higher in Japan than in the United States and European Union. BRONJ is refractory to treatment, and an efficient and useful therapy is not yet established.
双膦酸盐相关颌骨坏死（BRONJ）是长期使用双膦酸盐（BP）尤其是静脉制剂产生的一种副作用。该病变是一种新的疾病实体，于2003年在美国首次报道。从那时起，BRONJ患者的数量逐年增加。在日本，首例病例于2006年被报道，当时日本口腔颌面外科医师协会在全国范围内的调查中登记了30例BRONJ病例。然而，在两年后的第二次调查中，BRONJ患者数量迅速增加，确定了250多例符合临床诊断标准的BRONJ病例。在美国和欧盟，约95%的BRONJ患者接受静脉BP治疗，不到5%的患者接受口服BP治疗，而在日本，58%的患者接受静脉BP治疗，40%的患者接受口服BP治疗。在日本，与使用口服BP相关的BRONJ相对比例高于美国和欧盟。BRONJ治疗困难，尚未确立有效且有用的治疗方法。
